Hey all. Hope everyone is doing well. As promised, I will be posting things on here from time to time…2 or 3 articles per week perhaps. I wanted to pass along today’s article. My new website again is www.theoxengroup.com. Feel free to comment, and I will respond.
TGIF! Its been a tough, long week. We are holding three positions moving into the final day of the week, and we are looking to close shop on them. BIG had disappointing earnings at a penny miss on EPS and downgraded outlook. It was a disappointing report for them, and one I will have to spend some more time with since I like it longterm. We will be looking to exit this one at the open for the final 1/4 of the position we have left. We continue to hold TSL with an average entry at 23.20. We are looking to exit at 23.60s or higher. Finally, we are most likely going to just get rid of KERX to start the morning as it is near our stop loss of 4.90.
As for today, I will be looking to add a new Midterm Trade to the fold on today’s pullback, and we are going to have a new Longterm Ratings Report up with Chipotle Mexican Grill (CMG).
Good luck out there today!
Midterm Trade of the Day: Human Genome Sciences Inc. (HGSI)
Analysis: We are taking a look at a new position in a pharmaceuticals company Human Genome Sciences (HGSI). This company has some 
definite upward movement in its sights for next week. The reason behind its movement is due to the company’s approval date of its drug Benlysta on Thursday from FDA. The drug is a treatment drug for the ailment Lupus. If approved, it will be the first drug centered at targeting lupus in fifty years with no rival drugs and a market potential in the billions. The drug is very neat and creates antibodies that help cells remain alive when struck by Lupus.
The key, though, is if it gets approved. Leading up to its approval, the drug has hailed a ton of support from the Lupus community and various foundations that support the battle against lupus. Further, the drug had outstanding results from its tests. The drug met all its endpoint requirements in trials, and it was…
